4//SEC Filing
Shannon John Patrick Jr 4
Accession 0001867096-24-000145
CIK 0001867096other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 5:22 PM ET
Size
21.1 KB
Accession
0001867096-24-000145
Insider Transaction Report
Form 4
Shannon John Patrick Jr
DirectorSee Remarks
Transactions
- Award
Common Stock
2024-08-01+250,000→ 2,419,612 total - Tax Payment
Common Stock
2022-01-29$2.11/sh−15,692$33,110→ 2,403,920 total - Tax Payment
Common Stock
2022-01-31$2.11/sh−7,497$15,819→ 2,396,423 total - Tax Payment
Common Stock
2023-01-03$1.12/sh−41,334$46,294→ 2,355,089 total - Tax Payment
Common Stock
2023-01-29$1.26/sh−23,414$29,502→ 2,331,675 total - Tax Payment
Common Stock
2024-01-03$2.24/sh−40,834$91,468→ 2,280,961 total - Tax Payment
Common Stock
2023-01-31$1.24/sh−9,880$12,251→ 2,321,795 total - Tax Payment
Common Stock
2024-01-29$2.66/sh−22,150$58,919→ 2,258,811 total - Tax Payment
Common Stock
2024-01-31$2.46/sh−110,750$272,445→ 2,148,061 total - Award
Stock Appreciation Right
2024-08-01+300,000→ 300,000 totalExercise: $2.43Exp: 2026-09-01→ Common Stock (300,000 underlying)
Footnotes (13)
- [F1]These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
- [F10]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
- [F11]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.
- [F12]The award will vest in full on the two-year anniversary of the grant date.
- [F13]Upon exercise, the Stock Appreciation Right will be settled in cash.
- [F2]These shares include 11,037 shares that were purchased on June 30, 2024, due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
- [F3]This transaction is being reported late due to administrative oversight.
- [F4]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
- [F5]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
- [F6]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
- [F7]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
- [F8]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
- [F9]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001553595
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 5:22 PM ET
- Size
- 21.1 KB